Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.
Status:
Not yet recruiting
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label, phase II trial to determine the safety, tolerability, and
immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018
vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior
regimens.